![Shingo Nakamura](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Shingo Nakamura
Director/Board Member at REGiMMUNE Corp.
Shingo Nakamura active positions
Companies | Position | Start | End |
---|---|---|---|
REGiMMUNE Corp.
![]() REGiMMUNE Corp. Pharmaceuticals: MajorHealth Technology REGiMMUNE Corp. develops solutions for treating immune disorders. Its focus is on the discovery, development, and commercialization of immune regulatory therapeutics to treat life-threatening and debilitating conditions, including allergies, autoimmune diseases and transplantation. The firm's platform technology, reVax, induces immune tolerance in an antigen-specific manner through pharmacological induction of regulatory T (Treg) cells. It also develops products for preventing inhibitor formation in enzyme replacement therapies (ERT) and for celiac disease with undisclosed partners. The company was founded by Yasuyuki Ishii on March 3, 2006 and is headquartered in Tokyo, Japan. | Director/Board Member | - | - |
Career history of Shingo Nakamura
Former positions of Shingo Nakamura
Companies | Position | Start | End |
---|---|---|---|
PRISM BioLab Co., Ltd.
![]() PRISM BioLab Co., Ltd. BiotechnologyHealth Technology PRISM Pharma Co., Ltd. operates as a pharmaceutical company that focuses on discovery and development of small molecules to modulate protein-protein interactions. It utilizes protein secondary structure mimetic library, which modulates intracellular protein and protein interactions. The firm develops an anti-cancer drug CP/Catenin inhibitor PRI-724 that acts on both cancer cells and cancer stem cells that can switch from proliferation to differentiation. The company was founded by Hiroyuki Kouji on November 2, 2006 and is headquartered in Fujisawa, Japan. | Director/Board Member | - | - |
Training of Shingo Nakamura
MIT Sloan School of Management | Masters Business Admin |
Stanford University | Graduate Degree |
Waseda University | Undergraduate Degree |
Statistics
International
Japan | 4 |
United States | 3 |
Operational
Director/Board Member | 2 |
Masters Business Admin | 1 |
Graduate Degree | 1 |
Sectoral
Consumer Services | 4 |
Health Technology | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
![]() | Health Technology |
Private companies | 1 |
---|---|
REGiMMUNE Corp.
![]() REGiMMUNE Corp. Pharmaceuticals: MajorHealth Technology REGiMMUNE Corp. develops solutions for treating immune disorders. Its focus is on the discovery, development, and commercialization of immune regulatory therapeutics to treat life-threatening and debilitating conditions, including allergies, autoimmune diseases and transplantation. The firm's platform technology, reVax, induces immune tolerance in an antigen-specific manner through pharmacological induction of regulatory T (Treg) cells. It also develops products for preventing inhibitor formation in enzyme replacement therapies (ERT) and for celiac disease with undisclosed partners. The company was founded by Yasuyuki Ishii on March 3, 2006 and is headquartered in Tokyo, Japan. | Health Technology |
- Stock Market
- Insiders
- Shingo Nakamura
- Experience